Gilead is set to launch a Phase III trial of its once-yearly lenacapavir pre-exposure prophylaxis (PrEP) for human ...

Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against ...

Germany's financial markets watchdog is looking at whether Bayer fairly disclosed plans for shareholder approval of a capital ...

Gilead (NASDAQ:GILD) on Tuesday announced encouraging initial data from an ongoing Phase 1 trial for lenacapavir, an ...

Gilead Sciences announced a significant milestone: the U.S. FDA accepted their New Drug Applications (NDAs) for lenacapavir ...

Gilead Sciences set aside $200 million for a potential settlement with federal prosecutors to resolve an investigation into ...

After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price ...

Martin Scorsese and Apple Original Films are reportedly adapting Marilynne Robinson's Gilead novels with Leonardo DiCaprio ...

Warhammer 40,000: Wrath & Glory lets players build their groups from different archetypes. They are brought together as ...

Bernstein analyst Courtney Breen maintained a Buy rating on Gilead Sciences (GILD – Research Report) yesterday and set a price target of ...

The drug, which works by blocking HIV from entering and multiplying in human cells, remained in the body for at least 56 ...

Sciences presented the first data from its ongoing Phase 1 study investigating two novel, once-yearly formulations of ...